Skip to main content
Top
Published in: Globalization and Health 1/2009

Open Access 01-12-2009 | Research

Transparency in Nigeria's public pharmaceutical sector: perceptions from policy makers

Authors: Habibat A Garuba, Jillian C Kohler, Anna M Huisman

Published in: Globalization and Health | Issue 1/2009

Login to get access

Abstract

Background

Pharmaceuticals are an integral component of health care systems worldwide, thus, regulatory weaknesses in governance of the pharmaceutical system negatively impact health outcomes especially in developing countries [1]. Nigeria is one of a number of countries whose pharmaceutical system has been impacted by corruption and has struggled to curtail the production and trafficking of substandard drugs. In 2001, the National Agency for Food and Drug Administration and Control (NAFDAC) underwent an organizational restructuring resulting in reforms to reduce counterfeit drugs and better regulate pharmaceuticals [2]. Despite these changes, there is still room for improvement. This study assessed the perceived level of transparency and potential vulnerability to corruption that exists in four essential areas of Nigeria's pharmaceutical sector: registration, procurement, inspection (divided into inspection of ports and of establishments), and distribution.

Methods

Standardized questionnaires were adapted from the World Health Organization assessment tool and used in semi-structured interviews with key stakeholders in the public and private pharmaceutical system. The responses to the questions were tallied and converted to scores on a numerical scale where lower scores suggested greater vulnerability to corruption and higher scores suggested lower vulnerability.

Results

The overall score for Nigeria's pharmaceutical system was 7.4 out of 10, indicating a system that is marginally vulnerable to corruption. The weakest links were the areas of drug registration and inspection of ports. Analysis of the qualitative results revealed that the perceived level of corruption did not always match the qualitative evidence.

Conclusion

Despite the many reported reforms instituted by NAFDAC, the study findings suggest that facets of the pharmaceutical system in Nigeria remain fairly vulnerable to corruption. The most glaring deficiency seems to be the absence of conflict of interest guidelines which, if present and consistently administered, limit the promulgation of corrupt practices. Other major contributing factors are the inconsistency in documentation of procedures, lack of public availability of such documentation, and inadequacies in monitoring and evaluation. What is most critical from this study is the identification of areas that still remain permeable to corruption and, perhaps, where more appropriate checks and balances are needed from the Nigerian government and the international community.
Appendix
Available only for authorised users
Literature
1.
go back to reference Baghdadi-Sabeti G, Wondemagegnehu E: Measuring Transparency in Medicines Registration, Selection and Procurement, Four Country Assessment Studies. 2006, Geneva: World Health Organization Press Baghdadi-Sabeti G, Wondemagegnehu E: Measuring Transparency in Medicines Registration, Selection and Procurement, Four Country Assessment Studies. 2006, Geneva: World Health Organization Press
2.
go back to reference Cohen JC, Mrazek MF, Hawkins L: Corruption and Pharmaceuticals, Strengthening Good Governance to Improve Access. The Many Faces of Corruption Tracking Vulnerabilities at the Sector Level. Edited by: Campos JE, Pradhan S. 2007, Washington: The WorldBank Cohen JC, Mrazek MF, Hawkins L: Corruption and Pharmaceuticals, Strengthening Good Governance to Improve Access. The Many Faces of Corruption Tracking Vulnerabilities at the Sector Level. Edited by: Campos JE, Pradhan S. 2007, Washington: The WorldBank
3.
go back to reference Hanif M, Mobarak MR, Ronan A, Rahman D, Donovan JJ, Bennish ML: Fatal renal failure caused by diethylene glycol in paracetamol elixir: the Bangladesh epidemic. Br Med J. 1995, 311 (6997): 88-91.CrossRef Hanif M, Mobarak MR, Ronan A, Rahman D, Donovan JJ, Bennish ML: Fatal renal failure caused by diethylene glycol in paracetamol elixir: the Bangladesh epidemic. Br Med J. 1995, 311 (6997): 88-91.CrossRef
4.
go back to reference Newton PN, McGready R, Fernandez F, Green MD, Sunjio M, Bruneton C, Phanouvong S, Millet P, Whitty CJM, Talisuna AO, Proux S, Christophe EMl, Malenga G, Singhasivanon P, Bojang K, Kaur H, Palmer K, Day NPJ, Greenwood BM, Nosten F, White NJ: Manslaughter by fake artesunate in Asia - will Africa be next?. PLoS Med. 2006, 3 (6): e197-PubMedCentralCrossRefPubMed Newton PN, McGready R, Fernandez F, Green MD, Sunjio M, Bruneton C, Phanouvong S, Millet P, Whitty CJM, Talisuna AO, Proux S, Christophe EMl, Malenga G, Singhasivanon P, Bojang K, Kaur H, Palmer K, Day NPJ, Greenwood BM, Nosten F, White NJ: Manslaughter by fake artesunate in Asia - will Africa be next?. PLoS Med. 2006, 3 (6): e197-PubMedCentralCrossRefPubMed
5.
go back to reference O'Brien KL, Selaniko JD, Hecdivert C, Placide MF, Louis M, Barr DBC, James Hospedales CJ, Lewis MJ, Schwartz B, Philen RM, St. Victor S, Espindola J, Needham LL, Denerville K: Epidemic of pediatric deaths from acute renal failure caused by diethylene glycol poisoning. JAMA. 1998, 279 (15): 1175-80.CrossRefPubMed O'Brien KL, Selaniko JD, Hecdivert C, Placide MF, Louis M, Barr DBC, James Hospedales CJ, Lewis MJ, Schwartz B, Philen RM, St. Victor S, Espindola J, Needham LL, Denerville K: Epidemic of pediatric deaths from acute renal failure caused by diethylene glycol poisoning. JAMA. 1998, 279 (15): 1175-80.CrossRefPubMed
6.
go back to reference World Health Organization Department of Essential Drugs and Other Medicines: Counterfeit drugs: guidelines for the development of measures to combat counterfeit drugs. 1999, Geneva: World Health Organization Press World Health Organization Department of Essential Drugs and Other Medicines: Counterfeit drugs: guidelines for the development of measures to combat counterfeit drugs. 1999, Geneva: World Health Organization Press
7.
go back to reference Cohen JC: Pharmaceuticals and corruption: a risk assessment. Global Corruption Report 2006. 2006, 77-84. London: Transparency International Cohen JC: Pharmaceuticals and corruption: a risk assessment. Global Corruption Report 2006. 2006, 77-84. London: Transparency International
9.
go back to reference Erhun WO, Babalola OO, Erhun MO: Drug regulation and control in Nigeria: the challenge of counterfeit drugs. J Health Popul Dev Ctries. 2001, 4 (2): 23-4. Erhun WO, Babalola OO, Erhun MO: Drug regulation and control in Nigeria: the challenge of counterfeit drugs. J Health Popul Dev Ctries. 2001, 4 (2): 23-4.
12.
go back to reference The National Agency for Food and Drug Administration and Control (NAFDAC): NAFDAC destroys N10B fake drugs in 4 years. NAFDAC News. 2006, 1 (10): 4- The National Agency for Food and Drug Administration and Control (NAFDAC): NAFDAC destroys N10B fake drugs in 4 years. NAFDAC News. 2006, 1 (10): 4-
14.
go back to reference World Health Organization: Fake drugs: A scourge of the system. WHO Drug Inf. 1995, 9: 127-129. World Health Organization: Fake drugs: A scourge of the system. WHO Drug Inf. 1995, 9: 127-129.
15.
go back to reference Akunyil D: Counterfeit and Substandard Drugs, Nigeria's Experience: Implications, Challenges, Actions and Recommendations. Talk for NAFDAC at a Meeting for Key Interest Groups on Health. 2005, The World Bank Akunyil D: Counterfeit and Substandard Drugs, Nigeria's Experience: Implications, Challenges, Actions and Recommendations. Talk for NAFDAC at a Meeting for Key Interest Groups on Health. 2005, The World Bank
16.
go back to reference Shakoor O, Taylor R, Behrens R: Assessment of the incidence of substandard drugs in developing countries. Trop Med Int Health. 1997, 2 (9): 839-45.CrossRefPubMed Shakoor O, Taylor R, Behrens R: Assessment of the incidence of substandard drugs in developing countries. Trop Med Int Health. 1997, 2 (9): 839-45.CrossRefPubMed
17.
go back to reference Akunyili D: The fight against counterfeit drugs in Nigeria. Pharmaceuticals and corruption: a risk assessment. Global Corruption Report 2006. 2006, 96-99. London: Transparency International Akunyili D: The fight against counterfeit drugs in Nigeria. Pharmaceuticals and corruption: a risk assessment. Global Corruption Report 2006. 2006, 96-99. London: Transparency International
18.
go back to reference Nnani I: Baseline study to ascertain the level and quality of unregistered drugs on the market. 2001, National Food and Drug Administration and Control (NAFDAC) Nnani I: Baseline study to ascertain the level and quality of unregistered drugs on the market. 2001, National Food and Drug Administration and Control (NAFDAC)
19.
go back to reference Morris J, Stevens P: Counterfeit medicines in less developed countries: problems and solutions. 2006, London: International Policy Network: International Policy Press Morris J, Stevens P: Counterfeit medicines in less developed countries: problems and solutions. 2006, London: International Policy Network: International Policy Press
21.
go back to reference World Health Organization Department of Medicines Policy and Standards (PSM) and Department of Ethics, Trade, Human Rights, and Health Law (ETH) of the World Trade Organization: Measuring transparency to improve good governance in the public pharmaceutical sector: assessment instrument. Working document for field testing and revision (Rev I). 2007, Geneva: World Health Organization Press World Health Organization Department of Medicines Policy and Standards (PSM) and Department of Ethics, Trade, Human Rights, and Health Law (ETH) of the World Trade Organization: Measuring transparency to improve good governance in the public pharmaceutical sector: assessment instrument. Working document for field testing and revision (Rev I). 2007, Geneva: World Health Organization Press
22.
go back to reference Cohen JC, Cercone J, Macaya R: Improving transparency in the pharmaceutical system: the case of Costa Rica. 2002, Washington: The World Bank Cohen JC, Cercone J, Macaya R: Improving transparency in the pharmaceutical system: the case of Costa Rica. 2002, Washington: The World Bank
24.
go back to reference Raufu AI: Nigeria leads fight against "killer" counterfeit drugs. Bulletin of the World Health Organization. 2006, 84 (9): 685-764. Raufu AI: Nigeria leads fight against "killer" counterfeit drugs. Bulletin of the World Health Organization. 2006, 84 (9): 685-764.
25.
go back to reference Oparah AC, Eferakeya AE: Attitudes of Nigerian Pharmacists towards Pharmaceutical Care. Pharm World Sci. 2005, 27: 208-214.CrossRefPubMed Oparah AC, Eferakeya AE: Attitudes of Nigerian Pharmacists towards Pharmaceutical Care. Pharm World Sci. 2005, 27: 208-214.CrossRefPubMed
26.
go back to reference The National Agency for Food and Drug Administration and Control (NAFDAC): NAFDAC smashes water for injection syndicate. NAFDAC News. 2006, 1 (10): 47- The National Agency for Food and Drug Administration and Control (NAFDAC): NAFDAC smashes water for injection syndicate. NAFDAC News. 2006, 1 (10): 47-
27.
go back to reference Cohen JC, Montoya JC: Using technology to fight corruption in pharmaceutical purchasing: lessons learned from the Chilean experience. 2001, The World Bank Cohen JC, Montoya JC: Using technology to fight corruption in pharmaceutical purchasing: lessons learned from the Chilean experience. 2001, The World Bank
28.
go back to reference McMahon G: Regulatory capture: causes and effects. International Institute for Public Ethics (IIPE) Biennial Conference: 4-7. 2002, October : Brisbane, Australia McMahon G: Regulatory capture: causes and effects. International Institute for Public Ethics (IIPE) Biennial Conference: 4-7. 2002, October : Brisbane, Australia
29.
go back to reference Nuhu SZ: The Future of Pharmacy in Nigeria: The Challenges Ahead. Nigerian Journal of Pharmacy. 2003, 34: 11-14. Nuhu SZ: The Future of Pharmacy in Nigeria: The Challenges Ahead. Nigerian Journal of Pharmacy. 2003, 34: 11-14.
30.
go back to reference Alo A: Pharmacy in Nigeria. Am J of Health Syst Pharm. 2006, 63: 670-673. 10.2146/ajhp050399.CrossRef Alo A: Pharmacy in Nigeria. Am J of Health Syst Pharm. 2006, 63: 670-673. 10.2146/ajhp050399.CrossRef
31.
go back to reference Erhun WO, Demehin AI, Erhun MO: Impact of Global Pharmaceutical Mergers and Acquisitions on the Nigerian Pharmaceutical Industry. Journal of Medical Marketing. 2005, 5 (4): 370-382. 10.1057/palgrave.jmm.5040256.CrossRef Erhun WO, Demehin AI, Erhun MO: Impact of Global Pharmaceutical Mergers and Acquisitions on the Nigerian Pharmaceutical Industry. Journal of Medical Marketing. 2005, 5 (4): 370-382. 10.1057/palgrave.jmm.5040256.CrossRef
Metadata
Title
Transparency in Nigeria's public pharmaceutical sector: perceptions from policy makers
Authors
Habibat A Garuba
Jillian C Kohler
Anna M Huisman
Publication date
01-12-2009
Publisher
BioMed Central
Published in
Globalization and Health / Issue 1/2009
Electronic ISSN: 1744-8603
DOI
https://doi.org/10.1186/1744-8603-5-14

Other articles of this Issue 1/2009

Globalization and Health 1/2009 Go to the issue